Journal
VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE
Volume 47, Issue 5, Pages 1065-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cvsm.2017.05.001
Keywords
Cardiac; Stroke; Cardioembolic; Feline; Cat; Thrombosis
Categories
Funding
- Bristol-Myers Squibb/Sanofi joint venture
- Plavix
Ask authors/readers for more resources
Feline cardiogenic arterial thromboembolism (CATE) is a devastating disease whereby 33% of cats survive their initial event, although approximately 50% of mortality is from euthanasia. Short-term management focuses on inducing a hypocoagulable state, improving blood flow, and providing supportive care. Ideally, all cats should be given 72 hours of treatment to determine the acute clinical course. Preventive protocols include antiplatelet and/or anticoagulant drugs, with the only prospective clinical trial demonstrating that clopidogrel is superior to aspirin with a lower CATE recurrence rate and longer time to recurrent CATE. Newer anticoagulant drugs hold great promise in the future of managing this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available